A new study from Hiroshima University challenges the long-held belief that patient confidentiality should always take precedence in medicine. In their essay, published in The American Journal of Bioethics, Rie Iizuka, Shu Ishida, and Tsutomu Sawai critically assess philosopher M. K. Kilbride’s suggested framework for determining when healthcare professionals may disclose a patient’s genetic information without consent.

The authors argue that when it comes to genetic information, refusing to disclose risks to family members can perpetuate harm across generations, particularly for hereditary conditions such as cancer that often emerge only after individuals have children.

The Hiroshima team argues that Kilbride’s model, which requires six strict conditions all be met before disclosure, is too restrictive and the conditions can contradict each other in practice. For instance, when genetic testing and preventive care are widely available, relatives might learn of their risk through other means, thus technically forbidding disclosure. Yet in settings where such resources are scarce, relatives depend entirely on disclosure to learn their risk, but the information is deemed less useful because preventive measures are inaccessible.

“This paradox makes it nearly impossible for clinicians to act, even when silence may endanger others,” said Iizuka. “Our analysis shows that absolute confidentiality can unintentionally obstruct prevention, delay treatment, and cause harm.”

The authors point out that in countries like Japan, where access to preimplantation genetic testing remains limited, many people learn of genetic risks only after disease onset, when opportunities for early intervention have already been lost. They emphasize that when hereditary diseases in a parent manifest after a child is born, a refusal to share information can have multigenerational consequences, depriving offspring of knowledge that could guide their reproductive and medical choices.

To address these ethical and practical gaps, the authors propose a more flexible, context-sensitive approach. Here, rather than requiring all six conditions be met, disclosure is considered when a sufficient subset is satisfied. This, they argue, would promote a more balanced evaluation of confidentiality, family well-being, and public health.

“Ethical decision-making in genetics must move beyond rigid checklists,” said Sawai. “Doctors should be encouraged to engage with the moral complexity of each case and not automatically default to silence.”

In the new framework proposed by the Hiroshima team, patient privacy is viewed as one principle among several, rather than an absolute. Such an attitude, they say, will allow healthcare systems to better support informed families, prevent avoidable suffering, and foster a culture of shared responsibility in genetic medicine.